{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-23-031526","form_type":"8-K","ticker":"ENVB","cik":"0000890821","company_name":"Enveric Biosciences, Inc.","filed_at":"2023-09-01T23:59:59+00:00","discovered_at":"2026-05-14T18:03:36.904368+00:00","generated_at":"2026-06-11T00:51:44.315395+00:00","sec_items":["1.01","9.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Enveric Biosciences enters $10M ATM equity distribution agreement with Canaccord Genuity","bullets":["Initial offering limited to $2,392,514 due to public float restrictions under Form S-3 as of September 1, 2023.","Canaccord receives 3.0% commission on gross sales; Company to reimburse certain expenses.","Net proceeds for general corporate purposes: R&D, working capital, debt reduction, acquisitions.","Shares sold under existing effective shelf registration statement (File No. 333-257690).","Agreement includes customary representations, warranties, and indemnification provisions."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-23-031526","json":"https://secwatch.observer/filing/0001493152-23-031526.json","markdown":"https://secwatch.observer/filing/0001493152-23-031526.md","text":"https://secwatch.observer/filing/0001493152-23-031526.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/890821/000149315223031526/0001493152-23-031526-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/890821/000149315223031526/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-11T00:51:44.315395+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"b241adbc31c64fef10ee96a4bc257f9adaf42d75","claim":"Enveric Biosciences, Inc. entered into Equity Distribution Agreement with Canaccord Genuity LLC valued at up to $10.0 million (effective 2023-09-01).","evidence_excerpt":"On September 1, 2023, Enveric Biosciences, Inc. (the “Company”) entered into an Equity Distribution Agreement (the “Distribution Agreement”), with Canaccord Genuity LLC (“Canaccord”), pursuant to which the Company may offer and sell from time to time, through Canaccord as sales agent and/or principal, shares of common stock of the Company, par value $0.01 per share (the “Common Stock”), having an aggregate offering price of up to $10.0 million.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/890821/000149315223031526/0001493152-23-031526-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"atm program"},{"label":"Counterparty","value":"Canaccord Genuity LLC"},{"label":"Value","value":"up to $10.0 million"},{"label":"Effective","value":"2023-09-01"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}